natgillin/translations-raw huggingface dataset:
Skin and Soft Tissue Infections (SSTIs) 
Okužbe kože in mehkih tkiv (OKMT)
• Benign intracranial hypertension, in line with recent labelling changes made in the US in April 2012 for levofloxacin; These cases should be kept under closely monitoring and further discussed in future PSURs. 
• benigna intrakranialna hipertenzija, v skladu z nedavnimi spremembami označevanja za levofloksacin v ZDA aprila 2012.
In addition, this section of the SmpC was updated to reflect the core safety profile agreed in April 2011 as an outcome of the PSUR worksharing procedure. 
Poleg tega je bilo to poglavje povzetka glavnih značilnosti zdravila posodobljeno tako, da odraža osnovni varnostni profil, ki je bil sprejet aprila 2011 kot izid projekta z deljenim delom PSUR (z zadnjimi podatki dopolnjeno redno poročilo o varnosti zdravila).
Community-acquired pneumonia in patients with additional risk factors or requiring hospitalization, or in case of known or suspected bacterial resistance to commonly used classes of anti-infectives (according to history of patients or national and /or regional resistance data), or if previous antiinfective treatment has failed. 
Zunajbolnišnična pljučnica pri bolnikih z dodatnimi dejavniki tveganja ali pri bolnikih, ki potrebujejo hospitalizacijo, ali v primeru znane ali domnevne odpornosti bakterij na običajno uporabljene razrede protivnetnih zdravil (v skladu z anamnezo bolnikov ali nacionalnimi in/ali regijskimi podatki o odpornosti) ali če je bilo predhodno protivnetno zdravljenje neuspešno.
Based on the current available data, considering the current treatment guidelines and also taking into account the current SmPC wording for other fluororoquinolon products with regards this indication, the MAH proposed the following restricted wording: 
Na podlagi trenutno razpoložljivih podatkov in ob upoštevanju trenutnih smernic za zdravljenje ter trenutnega besedila glavnih značilnosti zdravila za druga zdravila s fluorokinoloni v zvezi s to indikacijo je imetnik dovoljenja za promet z zdravilom predlagal naslednje omejeno besedilo:
Levofloxacin is approved in the most three common RTIs indications: acute bacterial sinusitis (ABS), acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumonia (CAP). 
Levofloksacin je odobren za tri najpogostejše indikacije pri okužbah dihal: akutni bakterijski sinusitis (ABS), akutno eksacerbacijo kroničnega bronhitisa (AEKB) in zunajbolnišnično pljučnico (ZBP).
• Pyelonephritis and complicated urinary tract infections (see section 4.4) 
• pielonefritis in zapletene okužbe sečil (glejte poglavje 4.4)
• Uncomplicated cystitis (tablets only): 250 mg once daily for 3 days; 
• nezapleteni cistitis (samo tablete): 250 mg enkrat dnevno za 3 dni;
The Core Safety Profile (CSP) approved as an outcome of the PSUR work-sharing procedure finalised on 1 April 2011 was considered. 
Upoštevali so osnovni varnostni profil (CSP), ki je bil odobren 1. aprila 2011 kot izid projekta z deljenim delom PSUR (z zadnjimi podatki dopolnjeno redno poročilo o varnosti zdravila).
Acute bacterial sinusitis (adequately diagnosed according to national and/or local guidelines on the treatment of respiratory tract infections) in severe cases at risk of complications (such as frontal, sphenoidal, ethmoidal or pansinusitis), or in case of known or suspected bacterial resistance to commonly used classes of anti-infectives (according to history of patients or national and /or regional resistance data), or if previous anti-infective treatment has failed. 
Akutni bakterijski sinusitis (ustrezno diagnosticiran v skladu z nacionalnimi in/ali lokalnimi smernicami za zdravljenje okužb dihal) v hudih primerih s tveganjem za zaplete (kot so čelni, sfenoidalni, etmoidni ali pansinusitis), v primeru znane ali domnevne odpornosti bakterij proti običajno uporabljenim razredom protivnetnih zdravil (v skladu z anamnezo bolnikov ali nacionalnimi in/ali regijskimi podatki o odpornosti) ali če je bilo predhodno protivnetno zdravljenje neuspešno.
This indication was only approved in one MS for both tablets (for post-exposure prophylaxis and curative treatment of anthrax) and IV solution (for the curative treatment) since 2001 in accordance with national recommendations. 
Ta indikacija je odobrena samo v eni državi članici za tablete (za profilakso po izpostavitvi in za kurativno zdravljenje vraničnega prisada) in za i.v.
Complicated urinary tract infections (cUTIs) including pyelonephritis (PN) 
Zapletene okužbe sečil, vključno s pielonefritisom
The CSP was considered when harmonising the listed adverse reactions between national SmPCs of Tavanic. 
Pri usklajevanju neželenih učinkov med nacionalnimi povzetki glavnih značilnosti zdravila Tavanic je bil upoštevan osnovni varnostni profil (CSP).
Following all the changes in the SPC there are several corresponding changes to the Package Leaflet. 
Po spremembah povzetka glavnih značilnosti zdravila so več ustreznih sprememb vnesli še v navodilo za uporabo.
• Inhalation Anthrax: postexposure prophylaxis and curative treatment (see section 4.4). 
• inhalacijski vranični prisad: profilaksa po izpostavitvi in kurativno zdravljenje (glejte poglavje 4.4)
In this harmonisation procedure the MAH claimed for RTIs indications (restricted), SSTIs, complicated and uncomplicated UTIs, chronic bacterial prostatitis and anthrax treatment. 
V tem postopku usklajevanja imetnik dovoljenja za promet uveljavlja indikacije za zdravljenje okužb dihal (z omejitvami), okužb kože in mehkih tkiv, zapletenih in nezapletenih okužb sečil, kroničnega bakterijskega prostatitisa in vraničnega prisada.
Acute bacterial exacerbations of chronic bronchitis (adequately diagnosed according to national and/or local guidelines on the treatment of respiratory tract infections) in patients with severe underlying COPD and/or other risk factors, or in case of known or suspected bacterial resistance to commonly used classes of anti-infectives (according to history of patients or national and /or regional resistance data), or if previous anti-infective treatment has failed. 
Akutne bakterijske eksacerbacije kroničnega bronhitisa (ustrezno diagnosticirane v skladu z nacionalnimi in/ali lokalnimi smernicami za zdravljenje okužb dihal) pri bolnikih s hudo izhodiščno KOPB in/ali drugimi dejavniki tveganja, v primeru znane ali domnevne odpornosti bakterij na običajno uporabljene razrede protivnetnih zdravil (v skladu z anamnezo bolnikov ali nacionalnimi in/ali regijskimi podatki o odpornosti) ali če je bilo predhodno protivnetno zdravljenje neuspešno.
Therefore, levofloxacin is active against a diverse range of common causative pathogens for sinusitis, acute exacerbation of chronic bronchitis (AECB), community-acquired pneumonia (CAP), urinary tract infections (UTIs) and skin and soft tissue infections (SSTIs). 
Levofloksacin tako deluje proti številnim pogostim patogenom, ki povzročajo sinusitis, akutno eksacerbacijo (nenadno poslabšanje) kroničnega bronhitisa (AEKB), zunajbolnišnično pljučnico (ZBP), okužbe sečil ter okužbe kože in mehkih tkiv (OKMT).
Levofloxacin is currently indicated in adults for the treatment of respiratory tract infections (RTIs), SSTIs, complicated and uncomplicated UTIs and chronic bacterial prostatitis (CBP). 
Levofloksacin je trenutno indiciran za uporabo pri odraslih za zdravljenje okužb dihal, okužb kože in mehkih tkiv, zapletenih in nezapletenih okužb sečil ter kroničnega bakterijskega prostatitisa.
A 750 mg strength in film coated tablet and as solution for infusion 750 mg/150 ml was approved in some MS. 
V nekaterih državah članicah je bila odobrena jakost 750 mg za filmsko obložene tablete in 750 mg/150 ml za raztopino za infundiranje.
the CHMP has recommended the variation to the terms of the marketing authorisations for which the summary of product characteristics, labelling and package leaflets are set out in Annex III for Tavanic and associated names (see Annex I). 
• Odbor je soglašal z uskladitvijo povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo, ki so jo predlagali imetniki dovoljenja za promet z zdravili, je odbor CHMP priporočil spremembo pogojev dovoljenj za promet z zdravilom Tavanic in povezanimi imeni (glejte Prilogo I), katerih povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo so določeni v Prilogi III .
Inhalation Anthrax 
Inhalacijski vranični prisad
Due to the combination of the MRP and National granted MAs some divergent information has been identified in the product information (PI) for Tavanic. 
Zaradi kombinacije postopka z medsebojnim priznavanjem in nacionalno odobrenih dovoljenj za promet z zdravilom je bilo v informacijah o zdravilu Tavanic ugotovljenih nekaj razhajanj.
Tavanic, film-coated tablets, 250 mg and 500mg 
Usklajene terapevtske indikacije za zdravilo Tavanic, filmsko obložene tablete 250 mg in 500 mg ter za i.v.
Tablets - Inhalation Anthrax: post-exposure prophylaxis and curative treatment IV solution - Inhalation Anthrax: curative treatment 
tablete - inhalacijski vranični prisad: profilaksa po izpostavitvi in kurativno zdravljenje; i.v.
• AECB (tablets only): 250 - 500 mg once daily for 7 - 10 days; 
• AEKB (samo tablete): 250-500 mg enkrat dnevno za 7-10 dni;
Package Leaflet (PL) 
Priloga II
For the above-mentioned infections Tavanic should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections. 
Za zgoraj navedene okužbe se zdravilo Tavanic uporablja le, kadar se uporaba splošno priporočenih protibakterijskih sredstev za začetno zdravljenje teh okužb šteje za neustrezno.
• Community-acquired pneumonia 
• zunajbolnišnična pljučnica
Based on the review of all the data currently available, the MAH proposed to harmonise the wording for levofloxacin tablets and IV solution to be recommended in PN and complicated urinary tract infections with consideration being given to official guidance on the appropriate use of antibacterial agents. 
raztopino levofloksacina, tako da bo priporočeno zdravljenje pielonefritisa in zapletenih okužb sečil z upoštevanjem uradnih smernic za ustrezno uporabo protibakterijskih sredstev.
Tavanic film coated tablets is indicated for the treatment of AECB in adults only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections. 
Filmsko obložene tablete Tavanic so indicirane za zdravljenje AEKB pri odraslih osebah samo, kadar se uporaba splošno priporočenih protibakterijskih sredstev za začetno zdravljenje teh okužb šteje za neustrezno.
This indication has been approved for levofloxacin tablets in all MS identified above via nationally or MRP. 
Ta indikacija je bila odobrena za tablete levofloksacina v vseh naštetih državah članicah z nacionalnim postopkom ali postopkom z medsebojnim priznavanjem.
The most important pathogens in these indications are S. pneumoniae, H. influenzae with the addition of intracellular/atypical bacteria for CAP. Hospital-acquired pneumonia (HAP) is also a RTI for which levofloxacin was approved for in two MS and for which the MAH is not pursuing its maintenance as summarised below. 
Najpomembnejši patogeni pri teh indikacijah so S. pneumoniae, H. influenzae z dodanimi znotrajceličnimi/atipičnimi bakterijami za ZBP.
This indication has been approved in all MS for both tablets and IV formulation, except in one MS. 
Ta indikacija ni bila odobrena v vseh državah članicah za obe vrsti tablet in za i.v.
• cSSTIs (tablets): 250mg once daily or 500 mg once or twice daily for 7 to 14 days; 
• zapletene okužbe kože in mehkih tkiv (tablete): 250 mg enkrat dnevno ali 500 mg enkrat ali dvakrat dnevno za 7 do 14 dni;
Levofloxacin is also indicated in a few atypical indications like urosepsis, digestive and hepatobiliary infections, Anthrax curative treatment, and hospital-acquired pneumonia (HAP). 
Uporablja se tudi za nekatere atipične indikacije, kot so urosepsa, okužbe prebavil, jeter, žolčnika in žolčevodov, za zdravljenje vraničnega prisada in bolnišnične pljučnice.
The MAH agreed that Tavanic film coated tablets is indicated for the treatment of ABS in adults only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections. 
Imetnik dovoljenja za promet z zdravilom je soglašal, da so filmsko obložene tablete Tavanic indicirane za zdravljenje ABS pri odraslih samo, kadar se uporaba splošno priporočenih protibakterijskih sredstev za začetno zdravljenje teh okužb šteje za neustrezno.
The CAP indication is approved for both tablets and IV formulation of levofloxacin. 
Indikacija ZBP je odobrena za tablete in i.v.
Respiratory Tract Infections (RTIs) 
Zunajbolnišnična pljučnica (ZBP)
This indication is approved for both tablets and IV formulation of levofloxacin. 
Ta indikacija je odobrena za tablete in i.v.
Therefore, it was agreed to reflect in the SmPCs for both tablets and IV that Tavanic is indicated for the treatment of CAP in adults only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections. 
obliko odražati, da je zdravilo Tavanic indicirano za zdravljenje ZBP pri odraslih samo, kadar se uporaba splošno priporočenih protibakterijskih sredstev za začetno zdravljenje teh okužb šteje za neustrezno.
• cSSTIs (IV solution): 500 mg twice daily; 
raztopina): 500 mg dvakrat dnevno.
56 (4x14) tablets (multipack) 
56 (4x14) tablet (večkratno pakiranje)
Film-coated tablet Oral use blister (PVC/PE/PCTFE/Alu) 
12,5 mg/75 mg/50 mg filmsko obložena tableta peroralna uporaba pretisni omot (PVC/PE/PCTFE/Alu)
- 5.0 µg in 0.5 ml. 
v 0,5 ml.
Invented name Strength Pharmaceutical Form Route of Administration Packaging 
Številka EU Izmišljeno ime Jakost Farmacevtska oblika Pot uporabe
EU/1/99/104/001 Procomvax 
EU/1/99/104/001 Procomvax suspenzija za injiciranje intramuskularna uporaba viala (steklena)
Polyribosylribitol phosphate (PRP) from Haemophilus influenzae type b as PRP-OMPC -7.5 µg Neisseria meningitidis OMPC (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B) - 125 µg Adsorbed hepatitis B surface antigen produced in recombinant yeast cells(Saccharomyces cerevisiae) 
OMPC (outer membrane protein complex - beljakovinski kompleks zunanje membrane) Neisserie meningitidis (seva B11 Neisserie meningitidis podskupine B)
These measures will help protect the environment. 
S temi ukrepi pomagate varovati okolje.
7 days (1 week) 
7 dni (1 teden)
• Both you and your partner must use effective contraception. 
• Oba s partnerjem morata uporabljati učinkovito kontracepcijo.
This schedule is repeated in cycles of 4 weeks. 
Ta razpored ponavljate v 4-tedenskih ciklih.
There was no effect of food on the overall exposure (AUC). 
Hrana ni imela učinka na celotno izpostavljenost (AUC).
Each pack contains 1 bottle. 
Vsako pakiranje vsebuje 1 plastenko.
P-value (Log rank test) 
P-vrednost (Log rank test)
• Taste changes or loss of taste. 
• Sprememba okusa ali izguba okusa.
It was reported as serious in one patient. 
Poročali so o resnem primeru pri enem bolniku.
This includes herbal medicines and other medicines you have bought without a prescription. 
To vključuje zdravila rastlinskega izvora in druga zdravila, ki ste jih kupili brez recepta.
Tell your doctor immediately if you think you have high blood pressure. 
Zdravniku takoj povejte, če menite, da imate visok krvni tlak.
This treatment schedule should be continued until disease progression or unacceptable toxicity. 
Ta razpored zdravljenja je treba nadaljevati, dokler bolezen ne napreduje ali do nesprejemljive toksičnosti.
• Increased amount of protein in the urine. 
• Povečana količina beljakovin v urinu.
• Increase in number of red blood cells. 
• Povečano število rdečih krvnih celic.
Decreased appetite 
Zmanjšan apetit
The following terms have been combined: 
Naslednji izrazi so bili združeni v skupine:
It is unknown whether tivozanib is excreted in human milk, but the potential exists. 
Ni znano, ali se tivozanib izloča v človeško mleko, vendar obstaja verjetnost.
• Tiredness and lack of energy. 
• Utrujenost in pomanjkanje energije.
In the ITT population there was a small numerical difference between the two arms in terms of overall survival. 
V populaciji ITT je bila manjša razlika v številkah med dvema krakoma z vidika celokupnega preživetja.
Other medicines and Fotivda 
Druga zdravila in Fotivda
What Fotivda is and what it is used for 
Kaj je zdravilo Fotivda in za kaj ga uporabljamo
• Blocked ears. 
• Zamašena ušesa.
Taking with food and drink 
Zdravilo skupaj s hrano in pijačo
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. 
Pred začetkom jemanja tega zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
This medicine has not been studied in children and adolescents. 
To zdravilo ni bilo raziskano pri otrocih in mladostnikih.
Avoid driving or using machines if you feel weak, tired, or dizzy. 
Ne vozite ali upravljate strojev, če se počutite šibko, utrujeno ali omotično.
Study AV-951-09-301 
Študija AV-951-09-301
In approximately one-third of the patients, hypertension developed within the first 2 months of treatment. 
Pri približno tretjini bolnikov je hipertenzija nastopila v prvih 2 mesecih zdravljenja.
High blood pressure is the most serious and a very common side effect (see also in section 2 “Warnings and Precautions”). 
Visok krvni tlak je najresnejši in zelo pogost neželeni učinek (glejte tudi poglavje 2 „Opozorila in previdnostni ukrepi“).
Do not chew, dissolve or open the capsule before swallowing. 
Ne žvečite, raztapljajte ali odpirajte kapsule, preden jo pogoltnete.
Tell your doctor if you are taking any of the following medicines; they may decide to change your medication: 
Povejte zdravniku, če jemljete katero koli od naslednjih zdravil; morda se bo zdravnik odločil zamenjati zdravilo:
Do not take Fotivda: 
Zdravila Fotivda ne vzemite:
The capsules must be swallowed whole with a glass of water and must not be opened. 
Kapsule je treba pogoltniti z vodo in se jih ne sme odpirati.
It allows continued monitoring of the benefit/risk balance of the medicinal product. 
Omogoča stalno nadzorovanje razmerja med koristijo in tveganjem zdravila.
• nafcillin, rifampicin, rifabutin, rifapentin (antibiotics); 
• nafcillin, rifampicin, rifabutin, rifapentin (antibiotiki);
CYP and UGT in vitro studies 
CYP in UGT v študijah in vitro
Hypothyroidism should be treated according to standard medical practice. 
Hipotiroidizem je treba zdraviti po standardni medicinski praksi.
Do not give Fotivda to children and adolescents under 18 years of age. 
Ne dajte zdravila Fotivda otrokom in mladostnikom, mlajšim od 18 let.
Swallow the capsule whole. 
Pogoltnite celo kapsulo.
The most important serious adverse reaction is hypertension. 
Najpomembnejši resen neželeni učinek je hipertenzija.
Average Cmax and AUC0-24hr were not significantly affected (8% increase and 6% decrease respectively). 
Na povprečno Cmax in AUC0-24hr ni bilo pomembnega vpliva (8 % povečanje oziroma 6 % zmanjšanje).
• Abnormal electrocardiogram (ECG), rapid and/or irregular heart beat. 
• Nenormalen elektrokardiogram (EKG), hiter in/ali nepravilen srčni utrip.
• Sight problems including blurred vision. 
• Težave z vidom, vključno z zamegljenim vidom.
• Memory loss. 
• Izguba spomina.
If you or your partner are taking hormonal contraceptives (the pill, an implant or patch) you must use an additional barrier method throughout treatment and for another month after completing treatment. 
Če vi ali vaš partner jemljeta hormonsko kontracepcijo (tableta, vsadek ali obliž) morate uporabiti dodatno pregradno metodo ves čas zdravljenja in še en mesec po zaključenem zdravljenju.
• Difficulty speaking 
• Težave pri govoru.
What you need to know before you take Fotivda 
Kaj morate vedeti, preden vzamete zdravilo Fotivda
These are all symptoms of high blood pressure. 
To so vse simptomi visokega krvnega tlaka.
Contraindication of concomitant use 
Kontraindikacija za sočasno uporabo
See also Section 4 “Possible side effects”. 
Glejte poglavje 4 „Možni neželeni učinki“.
One patient experienced Grade 4 PRES and hypertension in Study AV-951-09-901. 
PRES 4. stopnje in hipertenzijo v študiji AV-951-09-901.
• Temporary reduced blood flow to the brain. 
• Začasno zmanjšan dotok krvi v možgane.
• rosuvastatin (a medicine used to help lower cholesterol levels in your blood); 
• rosuvastatin (zdravilo, ki pomaga znižati ravni holesterola v krvi);
The safety and efficacy of tivozanib in children and adolescents aged below 18 years have not been established. 
Varnost in učinkovitost tivozaniba pri otrocih in mladostnikih, mlajših od 18 let, še nista dokazani.
Fotivda must be taken with a glass of water and can be taken either with or without food. 
Zdravilo Fotivda je treba vzeti z vodo, jemlje se ga lahko s hrano ali brez nje.
• if you have high blood pressure. 
• če imate visok krvni tlak.
The majority of AST and ALT elevations were not accompanied with concomitant elevations of bilirubin. 
Večino povišanj AST in ALT ni spremljalo hkratno povišanje bilirubina.
In studies that evaluated the terminal elimination phase, tivozanib had a mean t½ of 4.5 - 5.1 days. 
V študijah, v katerih so proučevali fazo končnega izločanja, je imel tivozanib mediani t½ 4,5-5,1 dan.
• If you are allergic to tivozanib or any of the other ingredients of this medicine (listed in section 6); 
• Če ste alergični na tivozanib ali katero koli drugo sestavina tega zdravila (navedeno v poglavju
The next dose should be taken at the next scheduled time. 
Naslednji odmerek mora vzeti v naslednjem predvidenem času po razporedu.
Gastrointestinal perforation/fistula 
Gastrointestinalna perforacija/fistula
common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and not known (cannot be estimated from available data). 
Pogostost je določena, kot sledi: zelo pogosti (≥1/10); pogosti (≥1/100 do < 1/10); občasni (≥1/1.000 do < 1/100), redki (≥1/10.000 do < 1/1000) in neznana pogostnost (ni možno oceniti glede na razpoložljive podatke).
In vitro protein binding studies have shown that tivozanib is > 99% bound to plasma proteins. 
Rezultati študije in vitro vezave na proteine so pokazali, da je tivozanib > 99 % vezan na plazemske beljakovine.
Clearance is similar between acute and chronic dosing indicating no time dependent changes in PK. 
Očistek je med akutnem in kroničnem odmerjanju podoben, kar kaže, da ni časovno odvisnih sprememb v FK.
Tell your doctor who will discuss with you the risks of taking Fotivda to you and your child. 
Povejte zdravniku, ki vas bo poučil o tveganju jemanja zdravila Fotivda za vašega otroka.
QT/QTc interval prolongation may lead to an increased risk for ventricular arrhythmias. 
Podaljšanje intervala QT/QTc lahko vodi do povečanega tveganja za prekatno aritmijo.
Risk factors for proteinuria include high blood pressure. 
Dejavniki tveganja za proteinurijo vključujejo visok krvni tlak.
These may be symptoms of a condition called hand foot skin reaction. 
To so lahko simptomi stanja t. i. kožne reakcije roka-noga.
Risk factors for hypothyroidism include prior history of hypothyroidism and use of anti-thyroid medications. 
Dejavniki tveganja za hipotiroidizem vključujejo anamnezo hipotiroidizma in uporabo antitiroidnih zdravil.
No more than one dose of Fotivda must be taken per day. 
Na dan se sme vzeti samo en odmerek zdravila Fotivda.
Healthcare professions should be aware that elderly patients may be at increased risk of adverse reactions. 
Zdravstveni delavci morajo vedeti, da pri starejših bolnikih obstaja večje tveganje za neželene učinke.
It works by blocking the action of a protein called vascular endothelial growth factor (VEGF). 
Deluje tako, da zavira delovanje beljakovine, imenovane vaskularni endotelijski rastni faktor (VEGF).